user avatar
Manni Mohyuddin
@ManniMD1
Cancer doctor with interest in myeloma, supportive care, end of life, cost-effective/evidence-based care and med-ed. Views own.
Salt Lake City, UT
Joined June 2020
458
Following
12.8K
Followers
Posts
  • Pinned
    user avatar
    Manni Mohyuddin
    @ManniMD1
    Jan 30, 2022
    For those that just followed me: I tweet about plasma cell disorders. I feel strongly about end-of-life, medical education and calling out what I feel is wrong (such as bad control arms, hype etc) I write educational 🧵occasionally- compiled here👇 bit.ly/32JUGv3 #mmsm
  • user avatar
    Manni Mohyuddin
    @ManniMD1
    Oct 5, 2021
    So as a junior myeloma faculty, I see a lot of consults for MGUS. Heres a tweetorial on how to interpret light chain values in the setting of kidney disease, as light chains are often checked to look for plasma cell disorders when patients have CKD. 🧵 #mmsm #MedTwitter
  • user avatar
    Manni Mohyuddin
    @ManniMD1
    Jun 12, 2023
    Just out in @JAMAInternalMed, we highlight a mechanism to detect selection bias/confounding in observational studies by looking at Kaplan Meier curves. If the curves separate implausibly early, the findings are too good to be true! jamanetwork.com/journals/jamai… @VPrasadMDMPH
    314K
  • user avatar
    Manni Mohyuddin
    @ManniMD1
    Jul 8, 2022
    Ever wondered about the staging of myeloma? Why is it so confusing? Why are there three stages (as opposed to 4)? How many staging systems are there? What all contributes to risk? Heres a 🧵 that goes over the past, present and future of myeloma staging. Read on! #mmsm
  • user avatar
    Manni Mohyuddin
    @ManniMD1
    May 1, 2024
    Ten important observations about myeloma and its precursors that I often discuss with patients and teach to trainees in my clinic. An educational thread 🧵 #mmsm 1/
    117K
  • user avatar
    Manni Mohyuddin
    @ManniMD1
    Oct 12, 2023
    A very common consult that hematologists get is for MGUS in the setting of neuropathy. Are they associated? What diagnosis can explain the association? What workup needs to be ordered? In this thread, we do a deep-dive on this important topic/outline management. #mmsm 🧵 1/
    100K
  • user avatar
    Manni Mohyuddin
    @ManniMD1
    Feb 23, 2022
    I am not a key opinion leader, and I do not take any money from pharma. It is likely my opinion is irrelevant, but I thought I would offer the unfiltered truth about major pharma companies that make #mmsm drugs in a humorous and authentic way. Free consulting in this 🧵
  • user avatar
    Manni Mohyuddin
    @ManniMD1
    Dec 11, 2022
    When you meet your hematology soulmate for the first time after publishing 12 papers together @AaronGoodman33 #ASH22
  • user avatar
    Manni Mohyuddin
    @ManniMD1
    Feb 10, 2023
    The first randomized trial of CAR-T in multiple myeloma. nejm.org/doi/full/10.10… Ide-cel versus a choice of five regimens for relapsed multiple myeloma! Lots to learn and process from this trial- so let us get started with this deep-dive 🧵 #mmsm
    76K
  • user avatar
    Manni Mohyuddin
    @ManniMD1
    Jun 8, 2022
    This article broke my heart and reminded me of all the toxicity in academia. I never have condoned any harsh speech against anyone, but I do have reason to believe I am being referred to in this article. I will highlight some themes in this important 🧵
    Hematologic Oncology News | Blood Cancers Today
    From bloodcancerstoday.com
  • user avatar
    Manni Mohyuddin
    @ManniMD1
    Dec 12, 2023
    How to treat myeloma after #ASH23 -don’t treat high risk smoldering -do quads for transplant eligible (but no cd38 maintenance afterwards) -don’t do quads or carfilzomib in newly diagnosed frail/older patients -don’t do a salvage auto no matter how good the first auto was
    41K
  • user avatar
    Manni Mohyuddin
    @ManniMD1
    Nov 9, 2022
    I am excited to be on the @ASH_hematology News Daily editorial board, and will be covering/attending the meeting this year. In this 🧵, I will highlight the top 10 myeloma abstracts that most influence my thought and practice from the #ASH22 meeting! #mmsm
  • user avatar
    Manni Mohyuddin
    @ManniMD1
    Nov 12, 2022
    After ending two weeks on the BMT inpatient service, here is a 🧵 on my favorite BMT CTN trials that I teach to every new fellow/PA/NP/pharmacist/trainee on rounds. I love these trials, and look forward to the ongoing ones! (CAVEAT-trials simplified for purpose of 🧵) #bmtsm
  • user avatar
    Manni Mohyuddin
    @ManniMD1
    Mar 28, 2022
    Prophylactic anticoagulation and risk of DVT in myeloma- a 🧵 on the evidence, a few case vignettes, and some guidance (based on VERY imperfect evidence). Read on. #mmsm #medtwitter